Disc Medicine, Inc. (IRON)
| Market Cap | 2.54B +20.1% |
| Revenue (ttm) | n/a |
| Net Income | -245.89M |
| EPS | -6.56 |
| Shares Out | 38.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 541,829 |
| Open | 68.54 |
| Previous Close | 68.48 |
| Day's Range | 65.31 - 68.95 |
| 52-Week Range | 40.00 - 99.50 |
| Beta | 2.05 |
| Analysts | Strong Buy |
| Price Target | 103.17 (+56.11%) |
| Est. Earnings | Nov 5, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $103.17, which is an increase of 56.11% from the latest price.
News
Disc Medicine price target raised to $86 from $79 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Disc Medicine (IRON) to $86 from $79 and keeps an Overweight rating on the shares. The firm notes shares…
Disc Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Initial data for DISC-3405 in polycythemia vera showed strong efficacy and safety, with flexible dosing strategies and promising expansion into sickle cell and beta thalassemia. APOLLO and RALLY-MF trials are progressing well, and pipeline assets target broader anemia indications.
Disc Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted robust clinical progress across multiple programs, with APOLLO phase III data for bitopertin in EPP and end-of-phase II data for MF expected by year-end. Commercial and financial planning is conservative, with a cash runway into 2029 and ongoing investments in launch infrastructure.
Disc Medicine Transcript: Wells Fargo 21st Annual Healthcare Conference
DISC-3405 shows promising efficacy and safety in PV, with rapid trial progress and potential for frontline use. Bitopertin's APOLLO phase III trial is well-powered and targets a rare disease market, with launch strategies focused on engaged patients and centers of excellence. Oral therapies are expected to drive future market growth.
Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients
Disc Medicine (IRON) “presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera. The data, presented in a poster session at the 2026…
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Upcoming phase III data for bitopertin targets improved sunlight tolerance in porphyria, with robust trial design and high demand for expanded access. Selcodebart shows promise for broad anemia management in myelofibrosis, and first patient data for DISC-3405 in polycythemia vera will be presented at SOHO.
Disc Medicine Slides: Corporate presentation
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine price target raised to $90 from $85 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $90 from $85 and keeps an Overweight rating on the shares.
Disc Medicine reports Q2 EPS ($1.54), consensus ($1.77)
“The anticipated readout of the Phase 3 APOLLO trial of bitopertin in EPP in Q4 marks a significant milestone. We have continued driving forward on this program over the past…
Disc Medicine Slides: Corporate presentation
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
WATERTOWN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Earnings release: Q2 2026
Disc Medicine released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Disc Medicine Quarterly report: Q2 2026
Disc Medicine has published its Q2 2026 quarterly earnings report on July 30, 2026.
Disc Medicine Transcript: AGM 2026
The meeting established a quorum and proceeded with director elections, a say-on-pay vote, and auditor ratification, all of which were approved by stockholders. No questions were raised, and final results will be filed with the SEC.
Disc Medicine price target raised to $85 from $80 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $85 from $80 and keeps an Overweight rating on the shares after the company hosted a call to…
Disc Medicine Transcript: Study update
Bitopertin's phase III APOLLO study is on track for top-line data in Q4, with sustained efficacy and safety seen in HELIOS. Selcodebart showed robust, durable anemia responses in MF across all subgroups, while DISC-3405 advances in PV and sickle cell disease, with initial data expected later this year.
Disc Medicine Press release: Study update
Disc Medicine issued a press release on June 15, 2026, disclosing material business information to investors.
Disc Medicine Slides: Study update
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Transcript: Jefferies Global Healthcare Conference 2026
Key programs are advancing with pivotal data readouts and regulatory meetings expected by year-end. Bitopertin’s phase III trial in EPP is fully enrolled, with a differentiated mechanism targeting the root cause and commercial launch preparations underway.
Disc Medicine presents updated data from RALLY-MF trial at ASCO
Disc Medicine (IRON) presented updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago. In this updated data set,…